KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $16.4 billion.

  • Royalty Pharma's Non-Current Assets rose 7.69% to $17.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 billion, marking a year-over-year increase of 7.69%. This contributed to the annual value of $16.4 billion for FY2024, which is 8.69% up from last year.
  • Latest data reveals that Royalty Pharma reported Non-Current Assets of $16.4 billion as of FY2024, which was up 8.69% from $15.1 billion recorded in FY2023.
  • Royalty Pharma's 5-year Non-Current Assets high stood at $16.4 billion for FY2024, and its period low was $13.3 billion during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $15.1 billion (2023), whereas its average is $15.3 billion.
  • Its Non-Current Assets has fluctuated over the past 5 years, first rose by 14.68% in 2020, then declined by 2.59% in 2022.
  • Over the past 5 years, Royalty Pharma's Non-Current Assets (Yearly) stood at $13.3 billion in 2020, then rose by 9.86% to $14.6 billion in 2021, then dropped by 2.59% to $14.3 billion in 2022, then rose by 5.96% to $15.1 billion in 2023, then grew by 8.69% to $16.4 billion in 2024.